ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2201

Immunodeficiency-Related Monogenic Autoinflammatory Diseases; Expanding Spectrum of Immunodysregulation Disorders
Abstract Number: 2202

Evolving Phenotypic and Genotypic Spectrum of Human ISG15 and USP18 Deficiencies
Abstract Number: 2203

The Association of Autoantibodies with Clinical Manifestations and Long-term Outcomes in Juvenile- and Adult-onset Systemic Sclerosis
Abstract Number: 2204

Guidance for Stem Cell Therapy for Juvenile Systemic Sclerosis Patients
Abstract Number: 2205

Presence of Nailfold Capillary Changes Correlates with More Severe Organ Involvement in Juvenile Systemic Scleroderma. Results of the Juvenile Scleroderma Inception Cohort
Abstract Number: 2206

There Is No Difference in Major Organ Involvement Andantibody Pattern Between Diffuse and Limited Subtypejuvenile Onsetsystemic Scleroderma Patients
Abstract Number: 2207

Improvement Across Physician and Patient Reported Outcome Measures over a 24 Months-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Abstract Number: 2208

Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry
Abstract Number: 2209

Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis
Abstract Number: 2210

Comparison of Dual RF and Anti-CCP Seropositive, Single Seropositive, and Seronegative RA on Radiographic Changes, Flares, and Mortality
Abstract Number: 2211

Identifying Clinical Predictors of Difficult-to-Treat Rheumatoid Arthritis Using Machine Learning-based Techniques
Abstract Number: 2212

Seropositive Arthralgias: A Comprehensive Analysis of the Reuma-Check Cohort
Abstract Number: 2213

Microvascular and Macrovascular Endothelial Dysfunction in Rheumatoid Arthritis
Abstract Number: 2214

Confirming a Value for Rheumatoid Arthritis Flares Based on Changes in CDAI, SDAI and RAPID3
Abstract Number: 2215

Treat (Depression to Reach)-to-Target in Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].